Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VUITY: see ads on T.V. and sort of surprised, that they have drops to improve vision for general public.:
https://www.healio.com/news/ophthalmology/20220405/twicedaily-vuity-meets-primary-endpoint-in-phase-3-presbyopia-trial
RUBY: cut in half on endpoint reaction, but RUBY CSO remarks:
"“If you compare this to most other monotherapy studies, and this type of Phase I advanced solid tumor setting, that is really a terrific result,....”
https://ih.advfn.com/stock-market/NASDAQ/rubius-therapeutics-RUBY/stock-news/87795325/rubius-therapeutics-reports-updated-clinical-data
AUUD 2.03 LOD still did not buy any and missed rise against general market fall, waiting for under 2, as historically safe unless sudden news..
BWV: heard lock up date may be cause of mass sell-off, did not check details but makes most sense..
BWV do not know but threw a bid ( lottery bid) into this chaos.
TRVI:acting like a "traitor" going up 50% instead of going down after dilution pledge.
Looking into my bag of knowing nothing, but asked on national TV for the complete soundbite. I will agree that the mRNA could help as a "better" pathway for the vaccine traffic to conquer the cancer.............but I have a feeling there are armies of well suited
cancer friendlies waiting to be usefull to destroy the success of this strategy, unless future scientific foresight develops new multi signaling apparatus to further advantage success.
BWV : down $45 today but still higher than IPO!
C; CITI $40.40, hits new low as Copperman and elite heads drop head in long sulk.
BCTX 11.36 after mid Jan 6's only one bad hair day since (drop of more than 10%).
HOWL : armed with its own comic designation , also soared to almost double on molecule dribble, and besides the actual name for this respectable drug Co. is Werewolf.
PRQR 1.00 am a sucker in no man's land, on day it picks to repudiate market drop.
ANNX: I watch many in same pool, for the significant " sign of "conclusive"
evidence announcing proof.
ANNX: jobs depend on their ability to exploit and cash in the fuzziness before clarity confirms what they already have a good notion to believe, while standing on the mat labeled unmet cure.
SBFM:
Yikes a triple after some days, as a result of PR that molecules in a dish show promise,.......... years since market did not cool off to such news for more than hours.
.https://www.globenewswire.com/news-release/2022/04/05/2416581/35334/en/Sunshine-Biopharma-s-Newly-Designed-mRNA-Molecules-Prove-Effective-Against-Multidrug-Resistant-Cancer-Cells.html
ISPO 7.94 restart.
Know all about him before he came to IHUB and set up a new model.
ISPC 3.98 only one share grab which has Ja. written all over it.
Nice post I missed!
OT: Yep moderator ( and still "Designated") was most talented poster on IHUB, and think he had to escape the stench when he decided to stop posting eons ago
FWBI .76, small audience for that PR.
https://www.goldmanresearch.com/202203301344/Opportunity-Research/catalysts-abound-for-fwbi.html
ISPC 4.16 doubled down want still lower.
ISPC 4.45 I like here, hope for lower as has technicals and DD.
ISPO 8.55 no wait!
Insulin candy click:
https://www.nature.com/articles/d41586-022-00736-w
GLG .369 took too long.
ACER went back to 2.93.
Inflammation: Excellent link!........ and IMHO if I had to allocate the bulk of all research money to be spent , inflammation/(macrophages), would easily be at the top of my list.........maybe it's all about waste management necessary to tip some victory needles?.
Cancer research: these links tease a "high minded" argument without providing a better
breakdown of mutually exclusive choices. in the way cancer research money can be collected and spend most efficiently. IMHO, risky betting (funding) on uncertain outcomes by greedy investors offering crumbs of possible success, may still be the supreme model, and any flaws of this paradigm, mask the unsuccessful nuggets of discovery yet to be revealed. Any weakness in this system is always detrimental to a patient unable to improve their survival rate., but short of the Gov't funding a conceivably better standard, which they already do, albeit, far short of the public's willingness to be taxed "enough", the present inefficient collection and allocation of resources on cancer research and discovery, reliant predominately on market forces, can be dangerous to change.
https://www.axios.com/cancer-drugs-new-hope-b3058317-736a-4378-93f0-1b7953b14fba.html?deepdive=1&utm_source=newsletter&utm_medium=email&utm_campaign=newsletter_axiosdeepdives&stream=top
ISPO 8.21 for JAN. ZZZZZZZZ.
AUUD 2.12: sold last as could see 3's or 1.50's,
"s, need to reload gun if lower, as daily vol. drops.
INBP .71 only to buy cheapest here.
AUUD 2.23 all bets off, as new riders in this saddle.
AUUD no ,I am biggest pumper.
SBTX: They are shooting miraculous darts, hoping to match their failing candidate with a better one that showed some early promise, without a real theory prompting a reasonable reason for success with their stale candidate.
https://endpts.com/another-biotech-falls-on-hard-times-as-silverback-axes-lead-i-o-candidates-lays-off-more-than-a-fourth-of-staff/
"The company joins the parade of biotechs that have been forced to reevaluate their lead programs and reduce their workforces this quarter, as a bearish market continues to batter the sector."
AUUD 2.15 HOD loose players trying vol. either way, needs a real nugget to
point to tradable direction.
AUUD almost no after hour trading.
SBTX 3.57: layoffs but price holding?
FWBI 1.05 LOD, targets are a ruse.